Get the Stockscreener App
0.3956
0.15%
0.0006
BiomX Inc stock is traded at $0.3956, with a volume of 325.30K.
It is up +0.15% in the last 24 hours and down -75.58% over the past month.
BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
See More
Previous Close:
$0.395
Open:
$0.3982
24h Volume:
325.30K
Relative Volume:
0.06
Market Cap:
$4.67M
Revenue:
-
Net Income/Loss:
$-47.68M
P/E Ratio:
-0.0158
EPS:
-24.9619
Net Cash Flow:
$-23.09M
1W Performance:
-23.91%
1M Performance:
-75.58%
6M Performance:
-79.50%
1Y Performance:
-95.37%
1-Day Range:
$0.3941
$0.4023
1-Week Range:
$0.3941
$0.516
52-Week Range:
$0.3608
$14.71
BiomX Inc Stock (PHGE) Company Profile
Name
BiomX Inc
Sector
Industry
Phone
972 7 23942377
Address
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Compare PHGE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
0.3956 | 4.67M | 0 | -47.68M | -23.09M | -24.96 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-21 | Initiated | Ladenburg Thalmann | Buy |
BiomX Inc Stock (PHGE) Latest News
BiomX Inc. Announces Amendment to 2026 Equity Incentive Plan: 5.46 Million Additional Shares Approved – SEC 8-K Filing Highlights – Minichart - Minichart
BiomX Shareholders Approve Director, Expand Equity Incentive Plan - TipRanks
BiomX (NYSE: PHGE) holders approve director and expand equity plan - Stock Titan
BiomX Company Profile & Introduction - Moomoo
Transcript : BiomX Inc.Shareholder/Analyst Call - marketscreener.com
Price to sales forward of BiomX Inc. – BOATS:PHGE - TradingView
Enterprise value to revenue forward of BiomX Inc. – BOATS:PHGE - TradingView
Price to earnings forward of BiomX Inc. – BOATS:PHGE - TradingView
Enterprise value to EBITDA forward of BiomX Inc. – AMEX:PHGE - TradingView
BiomX Inc. Actuals & Estimates (AMEX:PHGE) - TradingView
BiomX’s DFSL brings 99% accurate counter-drone tech to ISC 2026 - Stock Titan
Enterprise value to EBITDA forward of BiomX Inc. – BOATS:PHGE - TradingView
BiomX, Next-Gen Counter Drone Solutions will be Showcased by DFSL at ISC 2026 - marketscreener.com
BiomX Announces DFSL to Showcase Next-Generation LADAR Counter-Drone and Perimeter Security Solutions at ISC 2026 - Quiver Quantitative
BiomX: Next-Gen Counter Drone Solutions will be Showcased by DFSL at ISC 2026 - GlobeNewswire
Biomx Inc (PHGE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BiomX Unveils Strategy as Defense Technology Holding Company - The Globe and Mail
PHGE Should I Buy - Intellectia AI
BiomX posts updated presentation outlining defense, DFSL stake, Zorronet platform and go‑forward strategy - TradingView
BiomX (NYSE: PHGE) outlines defense tech portfolio and growth plan - Stock Titan
BiomX Inc. Posts Updated Presentation Highlighting Defense-Sector Transition and Growth Strategy - Quiver Quantitative
BiomX Provides Update on Defense Technology Portfolio and Growth Strategy - 富途牛牛
Biomx Inc (PHGE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biomx Inc (PHGE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Biomx Inc (PHGE) Institutional Confidence - TradingKey
Biomx Inc (PHGE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biomx Inc (PHGE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Biomx Inc (PHGE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Biomx Inc (PHGE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biomx Inc (PHGE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BiomX Inc. (PHGE) Holds Steady Near Support as Small Gain Suggests Cautious RecoveryIntraday Profile - newsline.com
Deerfield group now holds 4.70% of BiomX (PHGE) stock, below 5% - Stock Titan
PHGE (NYSE American: PHGE) expands ATM capacity to $5.06M; prior $1.38M sold - Stock Titan
BiomX Inc. (PHGE) Q4 2025 Earnings: EPS Misses Estimates as Company Advances PipelineEarnings Miss Alert - newsline.com
Number of shareholders of BiomX Inc. – AMEX:PHGE - TradingView
PHGE Q4 2025 Earnings: Significant EPS Miss Amid Clinical-Stage LossesOne-Time Gain Impact - newsline.com
BiomX Wins NYSE Compliance Plan Extension to 2027 - The Globe and Mail
PHGE - Finviz
BiomX Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
BiomX (PHGE) wins NYSE American plan period after equity deficit warning - Stock Titan
BiomX Announces NYSE American Acceptance of Plan to Regain Compliance - The Manila Times
BiomX (PHGE) details Zorronet and Dr. Frucht Systems acquisition financials - Stock Titan
BiomX Inc. Publishes Review on the Future of AI in Security Industry by Zorronet CEO Idan Wasserman - Quiver Quantitative
BiomX: Zorronet’s AI Security Experts Provide In-Depth Review on Why Security AI Must Move Beyond Detection to Understanding in High-Stakes Global Events - The Manila Times
Why stadium security AI must learn crowd behavior, not just spot threats - Stock Titan
Large new equity pool and board election at BiomX (PHGE) 2026 meeting - Stock Titan
· Analyst Forecast - MLQ.ai
PHGE Q4 2025 Earnings: Wider-than-Expected Loss Sends Shares LowerEarnings Weakness Phase - newsline.com
BiomX Inc. Enters Line of Credit Agreement and Issues 12% Convertible Promissory Note – SEC 8-K Filing June 2026 - Minichart
BiomX Issues Restricted Shares Under Mandragola Credit Facility - The Globe and Mail
BiomX subsidiary launches mobile command app for operators - Investing.com
BiomX Inc Stock (PHGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):